98 related articles for article (PubMed ID: 22189710)
1. Genetic variability in the PRKCI gene and prostate cancer risk.
Campa D; Canzian F; Kaaks R
Cell Cycle; 2012 Jan; 11(2):209. PubMed ID: 22189710
[No Abstract] [Full Text] [Related]
2. Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population.
Li Q; Gu C; Zhu Y; Wang M; Yang Y; Wang J; Jin L; Zhu ML; Shi TY; He J; Ye D; Wei Q
Mol Carcinog; 2015 Aug; 54(8):632-41. PubMed ID: 24510606
[TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in PRKCI gene and risk of prostate cancer in a sample of Iranian Population.
Hashemi M; Shahkar G; Simforoosh N; Basiri A; Ziaee SA; Narouie B; Taheri M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(5):16-21. PubMed ID: 26475383
[TBL] [Abstract][Full Text] [Related]
4. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
Campa D; Hüsing A; Stein A; Dostal L; Boeing H; Pischon T; Tjønneland A; Roswall N; Overvad K; Østergaard JN; Rodríguez L; Sala N; Sánchez MJ; Larrañaga N; Huerta JM; Barricarte A; Khaw KT; Wareham N; Travis RC; Allen NE; Lagiou P; Trichopoulou A; Trichopoulos D; Palli D; Sieri S; Tumino R; Sacerdote C; van Kranen H; Bueno-de-Mesquita HB; Hallmans G; Johansson M; Romieu I; Jenab M; Cox DG; Siddiq A; Riboli E; Canzian F; Kaaks R
PLoS One; 2011 Feb; 6(2):e16914. PubMed ID: 21373201
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of
Hashimoto I; Sakamaki K; Oue N; Kimura Y; Hiroshima Y; Hara K; Maezawa Y; Kano K; Aoyama T; Yamada T; Yamamoto N; Ogata T; Ito H; Shiozawa M; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
Anticancer Res; 2019 Oct; 39(10):5715-5720. PubMed ID: 31570472
[TBL] [Abstract][Full Text] [Related]
6. PRKCI promotes immune suppression in ovarian cancer.
Sarkar S; Bristow CA; Dey P; Rai K; Perets R; Ramirez-Cardenas A; Malasi S; Huang-Hobbs E; Haemmerle M; Wu SY; McGuire M; Protopopov A; Jiang S; Liu JF; Hirsch MS; Chang Q; Lazar AJ; Sood AK; Drapkin R; DePinho R; Draetta G; Chin L
Genes Dev; 2017 Jun; 31(11):1109-1121. PubMed ID: 28698296
[TBL] [Abstract][Full Text] [Related]
7. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Yang YL; Chu JY; Luo ML; Wu YP; Zhang Y; Feng YB; Shi ZZ; Xu X; Han YL; Cai Y; Dong JT; Zhan QM; Wu M; Wang MR
Genes Chromosomes Cancer; 2008 Feb; 47(2):127-36. PubMed ID: 17990328
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of circ-PRKCI inhibits cell migration and proliferation in Hirschsprung disease by suppressing the expression of miR-1324 target PLCB1.
Zhou L; Li Y; Jiang W; Zhang H; Wen Z; Su Y; Wu F; Zhi Z; Shen Q; Li H; Xu X; Tang W
Cell Cycle; 2018; 17(9):1092-1101. PubMed ID: 29895226
[TBL] [Abstract][Full Text] [Related]
9. [Prostate carcinoma: higher COX-2 contents in advanced tumors].
Weiss J; Friedrich MG
Aktuelle Urol; 2004 Sep; 35(5):359-61. PubMed ID: 15383996
[No Abstract] [Full Text] [Related]
10. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer.
Wu D; Foreman TL; Gregory CW; McJilton MA; Wescott GG; Ford OH; Alvey RF; Mohler JL; Terrian DM
Cancer Res; 2002 Apr; 62(8):2423-9. PubMed ID: 11956106
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development.
Fukutome K; Watanabe M; Shiraishi T; Murata M; Uemura H; Kubota Y; Kawamura J; Ito H; Yatani R
Cancer Lett; 1999 Feb; 136(1):83-7. PubMed ID: 10211944
[TBL] [Abstract][Full Text] [Related]
12. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
13. Genetic approaches to studying protein kinase C: an introduction.
Messing RO
Methods Mol Biol; 2003; 233():453-4. PubMed ID: 12840528
[No Abstract] [Full Text] [Related]
14. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate.
Koren R; Ben Meir D; Langzam L; Dekel Y; Konichezky M; Baniel J; Livne PM; Gal R; Sampson SR
Oncol Rep; 2004 Feb; 11(2):321-6. PubMed ID: 14719062
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase C.
Parker PJ; Cook PP; Olivier AR; Pears C; Ways DK; Webster C
Biochem Soc Trans; 1992 May; 20(2):415-8. PubMed ID: 1397641
[No Abstract] [Full Text] [Related]
16. COX-2 gene promoter haplotypes and prostate cancer risk.
Panguluri RC; Long LO; Chen W; Wang S; Coulibaly A; Ukoli F; Jackson A; Weinrich S; Ahaghotu C; Isaacs W; Kittles RA
Carcinogenesis; 2004 Jun; 25(6):961-6. PubMed ID: 14754878
[TBL] [Abstract][Full Text] [Related]
17. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer.
Kote-Jarai Z; Easton D; Edwards SM; Jefferies S; Durocher F; Jackson RA; Singh R; Ardern-Jones A; Murkin A; Dearnaley DP; Shearer R; Kirby R; Houlston R; Eeles R;
Pharmacogenetics; 2001 Jun; 11(4):325-30. PubMed ID: 11434510
[TBL] [Abstract][Full Text] [Related]
18. Genetic manipulation of protein kinase C in vivo.
Toker A
Methods Mol Biol; 2003; 233():475-89. PubMed ID: 12840530
[No Abstract] [Full Text] [Related]
19. Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.
Qiao L; Zhao LY; Rong SB; Wu XW; Wang S; Fujii T; Kazanietz MG; Rauser L; Savage J; Roth BL; Flippen-Anderson J; Kozikowski AP
Bioorg Med Chem Lett; 2001 Apr; 11(8):955-9. PubMed ID: 11327599
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel cancer fusion genes using chromosome breakpoint screening.
Hua K; Lin CH; Chen YL; Lin CH; Ping YH; Jou YS; Chen CF
Oncol Rep; 2017 Apr; 37(4):2101-2108. PubMed ID: 28350097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
